| Cameron C Scott, OD | |
|
7600 S Highway 69a, Miami, OK 74354-1016 | |
| (918) 332-4312 | |
| (918) 332-4418 |
| Full Name | Cameron C Scott |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 23 Years |
| Location | 7600 S Highway 69a, Miami, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699898429 | NPI | - | NPPES |
| 1502433 | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2433 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeastern Tribal Health System | 7911893854 | 14 |
News Archive
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
Bacterin International Holdings, Inc. is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin's proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multli-level and deformity spinal applications.
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia, have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
A team of researchers from the London School of Hygiene & Tropical Medicine, working in partnership with colleagues from Senegal, has found that intermittent preventive malaria treatment of children under five has a dramatic impact on malaria frequency.
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached a settlement agreement with Diosynth, RTP ("Diosynth"). As previously noted, NeoPharm reported that it had entered into various contractual arrangements with Diosynth to secure access to manufacturing capacity for the potential manufacture and regulatory advancement of Cintredekin Besudotox through early 2008.
› Verified 3 days ago
| Provider Name | Northeastern Tribal Health System |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1871522532 PECOS PAC ID: 7911893854 Enrollment ID: O20040226000389 |
News Archive
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
Bacterin International Holdings, Inc. is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin's proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multli-level and deformity spinal applications.
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia, have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
A team of researchers from the London School of Hygiene & Tropical Medicine, working in partnership with colleagues from Senegal, has found that intermittent preventive malaria treatment of children under five has a dramatic impact on malaria frequency.
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached a settlement agreement with Diosynth, RTP ("Diosynth"). As previously noted, NeoPharm reported that it had entered into various contractual arrangements with Diosynth to secure access to manufacturing capacity for the potential manufacture and regulatory advancement of Cintredekin Besudotox through early 2008.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cameron C Scott, OD 7600 S Highway 69a, Miami, OK 74354-1016 Ph: (918) 332-4312 | Cameron C Scott, OD 7600 S Highway 69a, Miami, OK 74354-1016 Ph: (918) 332-4312 |
News Archive
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
Bacterin International Holdings, Inc. is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin's proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multli-level and deformity spinal applications.
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia, have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
A team of researchers from the London School of Hygiene & Tropical Medicine, working in partnership with colleagues from Senegal, has found that intermittent preventive malaria treatment of children under five has a dramatic impact on malaria frequency.
NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached a settlement agreement with Diosynth, RTP ("Diosynth"). As previously noted, NeoPharm reported that it had entered into various contractual arrangements with Diosynth to secure access to manufacturing capacity for the potential manufacture and regulatory advancement of Cintredekin Besudotox through early 2008.
› Verified 3 days ago
Dr. John Franklin Gray Iii, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2222 N Main St, Miami, OK 74354 Phone: 918-540-1929 Fax: 918-542-7796 | |
Dr. John Arthur Mcferron, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 16 2nd Ave Nw, Miami, OK 74354 Phone: 918-542-2020 Fax: 918-542-9806 | |
John A. Mcferron, O.d. Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 16 2nd Ave Nw, Miami, OK 74354 Phone: 918-542-2020 Fax: 918-542-9806 | |
Scotti Brett Freeman, OD Optometrist Medicare: Medicare Enrolled Practice Location: 7600 S Highway 69a, Miami, OK 74354 Phone: 918-542-1655 Fax: 855-745-3601 | |
Eye Associates Of Miami, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 2222 N Main St, Miami, OK 74354 Phone: 918-542-1929 Fax: 918-542-7796 | |
A. Clark Mcquigg Iii, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2222 N Main St, Miami, OK 74354 Phone: 918-542-1929 Fax: 918-542-7796 |